Forum Πρωτοβάθμιας Φροντίδας Υγείας
ΠΦΥ -Εκπαίδευση => Αποσπάσματα από τον έντυπο & ηλεκτρονικό τύπο => Μήνυμα ξεκίνησε από: Argirios Argiriou στις 15 Ιανουαρίου 2015, 07:17:03
-
January 13, 2015
Jamaluddin Moloo, MD, MPH reviewing Sundström J et al. Ann Intern Med 2014 Dec 23.
A modest reduction in blood pressure might prevent stroke or death.
Clinical trials have shown convincingly that treating patients who have stage 2 hypertension (systolic blood pressure [BP] ≥160 mm Hg or diastolic BP ≥100 mm Hg) prevents adverse cardiovascular events and deaths; whether this is true for patients with mild hypertension is less clear. In this meta-analysis, investigators in Sweden assessed data from 13 randomized trials (>15,000 patients) to determine whether pharmacologic BP reduction in patients with stage 1 hypertension (systolic BP 140–159 mm Hg or diastolic BP 90–99 mm Hg) lowered risk for adverse cardiovascular events and deaths. Trials were included if ≥80% of participants had stage 1 hypertension and no apparent cardiovascular disease.
During median follow-up of 4.5 years, average BP reduction in treated versus control patients was 3.6/2.4 mm Hg. Odds ratios indicated significant reductions in stroke (0.72), cardiovascular-related deaths (0.75), and overall deaths (0.78). Differences in adverse cardiovascular events, adverse coronary events, and heart failure did not reach statistical significance.
Comment
This meta-analysis indicates that treating patients with stage 1 hypertension lowers risk for stroke and death.
Citation(s):
Sundström J et al. Effects of blood pressure reduction in mild hypertension: A systematic review and meta-analysis. Ann Intern Med 2014 Dec 23; [e-pub ahead of print]. (http://dx.doi.org/10.7326/M14-0773)
- See more at: http://www.jwatch.org/na36610/2015/01/13/should-patients-with-mild-hypertension-be-treated?query=etoc_jwgenmed#sthash.TlUZ3cWm.dpuf